Merck Targets Sandoz, Intas Over Generic Emend Plans

Law360, New York (June 5, 2012, 9:34 PM EDT) -- Merck Sharp & Dohme Corp. is suing Novartis AG unit Sandoz Inc. and India-based Intas Pharmaceuticals Ltd., claiming their plans to make a generic version of Merck's anti-nausea drug Emend would infringe two patents.

In two complaints filed May 31 and June 1 in the District of New Jersey, Merck said the abbreviated new drug applications filed by Sandoz and Intas' American unit Accord Healthcare Inc. infringe U.S. Patent Numbers 5,691,336 and 5,716,942, held by Merck.

Merck is asking for an injunction preventing Sandoz and Accord...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.